GlaxoSmithKline PLC at Guggenheim Vaccine and Infectious Disease Conference (Virtual) Transcript
Okay. Thanks, everybody, and thanks for joining us this afternoon for a fireside chat with GlaxoSmithKline. I'm Seamus Fernandez, Guggenheim's Global Pharmaceuticals Analyst. I'm joined by Rino Rappuoli, Glaxo's Chief Scientist and Head of Vaccines. Rino is a well-renowned vaccine scientist, most notably having pioneered the genomic approach to vaccine development, known as reverse vaccinology, the technology underpinning Bexsero. He joined GSK in 2015 upon the acquisition of Novartis Vaccines, where he served as Global Head of R&D for Novartis Vaccines.
So maybe just to kick us off. Rino, thank you so much for joining us today. I know that it's late in Italy, but really appreciate you joining us. So just to begin with, hoping that you could walk us through a little bit of the technology platforms that Glaxo really brings to the table across vaccines and infectious disease.
I know you've got mRNA adjuvant technology, glycoconjugates, viral vectors, but love to know
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
